Sandoz Inc said it has pantoprazole sodium for injection, 40 mg to Civica Rx to supply hospitals in the United States it serves. This is as part of a multiyear partnership to help reduce supply shortages, with several other medicines on the way before the end of 2020.
Since entering into the agreement in July, Pantoprazole is the first Sandoz medicine to ship to Civica. It is a proton pump inhibitor indicated in adults for the short-term treatment (seven to 10 days) of gastroesophageal reflux disease (GERD), linked with a history of erosive esophagitis.
Earlier, Sandoz announced it will supply six injectable medicines under the Civica private label to its 1,200 US hospitals.
The pact is being expanded to include an additional medicine to regulate blood pressure, which is frequently used to treat Covid-19 patients in hospitals.
Carol Lynch, President, Sandoz Inc, said, “Our collaboration with Civica is providing certainty for hospitals, doctors and patients who are too often frustrated by shortages of medicines. This is especially important as healthcare providers continue to manage the Covid-19 pandemic.”
He said they are committed to ensuring our medicines are there for the patients who need them when they need them.
Civica, a non-profit initiative, was started in 2018 by leading United States hospital systems concerned about generic drug shortages and philanthropic organizations passionate about improving healthcare.
Till date, over 50 health systems are Civica members, representing over 1,200 US hospitals and approximately 30 percent of all licensed US hospital beds including acute care.
(With inputs from The OnLook News Research Bureau)